Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacey M Fernandes

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Oncotarget|July 23, 2016
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignanciesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood|May 29, 2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemiaRachel Thijssen, Johanna Ter Burg, Brett Garrick, et al.
Blood Advances|October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Filippo Utro, Qing Wang, et al.
Oncotarget|April 16, 2016
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignancesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Cell|February 19, 2013
Evolution and impact of subclonal mutations in chronic lymphocytic leukemiaDan A Landau, Scott L Carter, Petar Stojanov, et al.
Blood|November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitorsSonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.
Cancer Cell|December 10, 2014
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemiaDan A Landau, Kendell Clement, Michael J Ziller, et al.
Nature|May 31, 2019
Growth dynamics in naturally progressing chronic lymphocytic leukaemiaMichaela Gruber, Ivana Bozic, Ignaty Leshchiner, et al.
Blood Cancer Discovery|February 19, 2021
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and TherapyHelene Kretzmer, Anat Biran, Noelia Purroy, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Oncotarget|July 23, 2016
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignanciesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood|May 29, 2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemiaRachel Thijssen, Johanna Ter Burg, Brett Garrick, et al.
Blood Advances|October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Filippo Utro, Qing Wang, et al.
Oncotarget|April 16, 2016
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignancesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Cell|February 19, 2013
Evolution and impact of subclonal mutations in chronic lymphocytic leukemiaDan A Landau, Scott L Carter, Petar Stojanov, et al.
Blood|November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitorsSonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.
Cancer Cell|December 10, 2014
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemiaDan A Landau, Kendell Clement, Michael J Ziller, et al.
Nature|May 31, 2019
Growth dynamics in naturally progressing chronic lymphocytic leukaemiaMichaela Gruber, Ivana Bozic, Ignaty Leshchiner, et al.
Blood Cancer Discovery|February 19, 2021
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and TherapyHelene Kretzmer, Anat Biran, Noelia Purroy, et al.
Pageof 6